RAFAEL HOLDINGS, INC. Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect
RAFAEL HOLDINGS, INC. (RFL) reported Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect of $102.00 thousand for the 3-month period ending 2023-04-30, per its 10-Q filed 2023-06-13.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect · last filed 2023-06-13
- RAFAEL HOLDINGS, INC. fair value, debt instrument, valuation techniques, change in technique, quantification of effect for the quarter ending 2023-04-30 was $102.00K.
| Period end | Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect 3 month | Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect 9 month |
|---|---|---|
| 2023-04-30 | $102.00K 10-Q · filed 2023-06-13 | $102.00K 10-Q · filed 2023-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |